U.S., Feb. 4 -- ClinicalTrials.gov registry received information related to the study (NCT06805617) titled 'A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers' on Jan. 28.
Brief Summary: The goal of this study is to evaluate the efficacy and safety of Ivonescimab in participants with advanced, metastatic salivary gland cancers.
The name of the study drug involved in this study is:
-Ivonescimab (a type of antibody)
Study Start Date: March 01
Study Type: INTERVENTIONAL
Condition:
Salivary Gland Cancer
Advanced Salivary Gland Carcinoma
Metastatic Salivary Gland Cancer
Adenoid Cystic Carcinoma
Intervention:
DRUG: Ivonescimab
An immunoglobulin (Ig) G1 monoclonal antibody (mAb), single-use vial,...